

Daily evidence digest

1 February 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Demand and occupancy in Australian EDs during the pandemic, social distancing and vaccinations, Novavax phase 3 trials

Peer reviewed journals featured:

- A retrospective analysis of demand and occupancy in Australian Emergency Departments [here](#)
- Commentary on insights from SARS-CoV-2 genetic sequences [here](#)

Letters and correspondence discussed:

- Duration of transmission of culturable SARS-CoV-2 [here](#)
- Social distancing remains key during vaccinations [here](#)
- Interim use of single dose of mRNA vaccines in the US – perspectives for [here](#) and against [here](#)

Guidance and reports

- The Cochrane Library released an update to its collection on evidence relevant to critical care [here](#)
- The Lowy Institute published a global COVID-19 performance index [here](#)
- The Australian Department of Health COVID-19 released its fortnightly epidemiology report [here](#)

News and blogs

- Vaccine makers ponder how to adapt to virus variants [here](#)
- Novavax released phase 3 trial results for its protein subunit vaccine (NVX-CoV2373), reporting a of 89.3% efficacy (using symptomatic disease as the primary endpoint) in the UK and 49.4% in South Africa. Data suggested that people who had previously been infected with the original virus were not protected against re-infection by the South African variant (501Y.V2), [here](#) and [here](#)

[Click here](#) to subscribe to the daily evidence digest.